GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Valuation Rank

Viatris (Viatris) Valuation Rank


View and export this data going back to 1986. Start your Free Trial

What is Viatris Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Viatris Valuation Rank Related Terms

Thank you for viewing the detailed overview of Viatris's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (Viatris) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Valuation Rank
Comparable Companies
NBIX CTLT ELAN ITCI ALKS PRGO LNTH PBH ALVO AMPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 XSWX:SDZ SZSE:000538 BOM:500124
Traded in Other Exchanges
MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Website
https://www.viatris.com
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
Andrew Cuneo officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni officer: President, Greater China 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury director, officer: Executive Chairman BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell director
Brian Roman officer: Global General Counsel 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts director 120 PARK AVE, NEW YORK NY 10017
Melina E Higgins director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL